# TARGET-D 203 (NCT07659795)

> A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

No report yet. It can be ordered.

- Drugs tested: VS-7375; VS-7375 plus cetuximab; VS-7375 plus cetuximab plus mFOLFOX6
- Indication: metastatic KRAS G12D-mutated colorectal adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07659795
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Verastem, Inc.
- Conditions: Colorectal Cancer
- Interventions: VS-7375; cetuximab; panitumumab; Cetuximab + mFOLFOX6
- Enrollment: 150
- Primary outcome: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
- Primary outcome: To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC
- Primary outcome: To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC

## Indexed commentary on TARGET-D 203 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=target-d-203-nct07659795
